The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1130
May 13, 2002
View Complete Issue         Table of Contents 2019 
Pegfilgrastim (Neulasta) For Prevention of Febrile Neutropenia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pegfilgrastim (Neulasta) For Prevention of Febrile Neutropenia
May 13, 2002 (Issue: 1130)
Recombinant human granulocyte colony stimulating factor (G-CSF, filgrastim) conjugated to polyethylene glycol (pegfilgrastim, Neulasta - Amgen) has been approved by the FDA for use in neutropenic patients with non-myeloid malignancies who are at high...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegfilgrastim (Neulasta) For Prevention of Febrile Neutropenia
Article code: 1130b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.